Table 1.
Baseline characteristics of participants
| Characteristics | n = 619 | Mean (SD) or % |
|---|---|---|
| Age at recruitment (years) | 619 | 62.0 (4.9) |
| Height (m) | 610 | 1.76 (0.06) |
| Weight (kg) | 618 | 84.2 (12.0) |
| BMI (kg/m2) | 610 | 27.1 (3.5) |
| Time since diagnosis (months) | 619 | 17 (9) |
| Serum IGF concentrations (nmol/mL) | ||
| IGF-I | 619 | 22.0 (7.1) |
| IGFBP-3 | 607 | 160.2 (34.5) |
| Ethnicity | ||
| White | 607 | 98.1 |
| Others | 5 | 0.8 |
| Unknown | 7 | 1.1 |
| Occupational class | ||
| Managerial | 273 | 44.1 |
| Intermediate | 99 | 16.0 |
| Working | 238 | 38.5 |
| Unknown | 9 | 1.4 |
| Family history of prostate cancer | ||
| Yes | 54 | 8.7 |
| No | 512 | 82.7 |
| Do not know | 41 | 6.6 |
| Unknown | 12 | 2.0 |
| Diabetes | ||
| Yes | 33 | 5.3 |
| No | 541 | 87.4 |
| Unknown | 45 | 7.3 |
| PSA level | ||
| <10.0 ng/mL | 549 | 88.7 |
| 10.0–20.0 ng/mL | 70 | 11.3 |
| Treatment | ||
| Active monitoring | 275 | 44.4 |
| Prostatectomy | 176 | 38.4 |
| Radiotherapy | 167 | 27.0 |
| Other | 1 | 0.2 |
| Gleason gradea | ||
| Low (2–6) | 450 | 72.7 |
| High (7–10) | 169 | 27.3 |
| Vitamin/dietary supplement intake | ||
| Yes | 324 | 52.3 |
| No | 282 | 45.6 |
| Unknown | 13 | 2.1 |
aGleason scores of 2, 3, and 4 were acceptable when the ProtecT trial was conducted as it was before the 2005 International Society of Urological Pathology [44]